Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and effectiveness of 2 drugs, perifosine in
combination with temsirolimus in children with solid tumors. Neither drug is currently part
of the standard treatment of solid tumors in children. Both drugs have been tested alone to
treat solid tumors in children with little success. There is now new insight that if given
together, perifosine and temsirolimus may work together to stop the growth of solid tumors
and may also make them shrink. The doctor wants to find out what effects; good and/or bad,
perifosine in combination with temsirolimus has on the patient and the cancer. The doctors
are testing four different dose schedules of perifosine with temsirolimus and the patient
will be asked to partake in one of the dose schedules. The dose schedule will be lower for
those enrolled early in the study.
Phase:
Phase 1
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
AEterna Zentaris Duke University NATL COMP CA NETWORK Pfizer University of Wisconsin, Madison